Axsome Therapeutics (AXSM) Research & Development (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Research & Development data on file, last reported at $52.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 17.62% year-over-year to $52.7 million; the trailing twelve-month figure through Mar 2026 stood at $145.0 million (down 25.66% YoY), and the FY2025 full-year result was $183.3 million, down 2.03% from the prior year.
• Research & Development rose to $52.7 million in Q1 2026, from $2.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $55.0 million in Q4 2024 to a low of $2.6 million in Q4 2025.
• A 5-year average of $31.3 million and a median of $30.8 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 142.23% in 2024 and slumped 95.27% in 2025, its largest moves.
• Tracing AXSM's Research & Development over 5 years: stood at $14.7 million in 2022, then soared by 109.64% to $30.8 million in 2023, then soared by 78.57% to $55.0 million in 2024, then tumbled by 95.27% to $2.6 million in 2025, then jumped by 1926.04% to $52.7 million in 2026.
• Business Quant data shows AXSM's Research & Development at $52.7 million in Q1 2026, $2.6 million in Q4 2025, and $40.2 million in Q3 2025.